American Journal of Cardiovascular Drugs

, Volume 11, Issue 6, pp 401–409

Comparing Antihypertensive Effect and Plasma Ciclosporin Concentration between Amlodipine and Valsartan Regimens in Hypertensive Renal Transplant Patients Receiving Ciclosporin Therapy

  • Jingjing Cai
  • Zhijun Huang
  • Guoping Yang
  • Ke Cheng
  • Qifa Ye
  • Yingzi Ming
  • Xiaocong Zuo
  • Peipei Zhou
  • Hong Yuan
Original Research Article

Abstract

Background

Hypertension, a major complication in kidney transplant recipients, is associated with premature death and graft loss. However, an optimal antihypertensive therapy for these patients has not been established [Chinese Clinical Trial Registry No. ChiCTR-TRC-10001071].

Objective

The aim of the present study was to evaluate the effect of amlodipine and valsartan on BP control in renal transplant patients and to analyze the correlation between cytochrome P450 (CYP) 3A5 or multidrug resistance-1 gene (MDR1) genotype and the antihypertensive effect of these two regimens.

Methods

150 renal transplant patients with stage 1 or 2 hypertension were enrolled in the trial. Patients were randomly assigned to amlodipine or valsartan. Metoprolol was added if BP was not under control after 4 weeks. BP and plasma levels of ciclosporin were monitored during the 24-week trial. CYP3A5 and MDR1 genotypes were determined using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results

The demographic features and baseline BP were similar between these two groups. During the 24-week trial, the reduction of systolic BP (SBP) was similar between the amlodipine and valsartan groups. However, the reduction of diastolic BP (DBP) was significantly greater in the amlodipine group compared with the valsartan group at 12, 16, and 24 weeks of treatment. The plasma level of ciclosporin at 2 hours of medication was significantly higher in the amlodipine group than in the valsartan group after 4 weeks of the trial. The reduction of DBP at 24 weeks was greater in the subjects with CYP3A5 *3/*3 variant than in those with CYP3A5*1/*1 variant (−13.5± 1.9mmHg vs −8.7± 1.6mmHg, p<0.05).

Conclusion

The present study demonstrated that amlodipine produced a greater reduction of DBP than valsartan, although both amlodipine and valsartan resulted in satisfactory control of BP in patients with renal transplantation. Administration of amlodipine significantly increased the plasma concentration of ciclosporin, and its effects on BP control and ciclosporin concentration may be associated with the CYP3A5 genotype in these subjects [Chinese Clinical Trial Registry No. ChiCTR-TRC-10001071].

References

  1. 1.
    Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 Suppl. 1: 121–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Morales JM, Dominguez-Gil B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens 2005 Sep; 23(9): 1609–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Hricik DE, Chareandee C, Knauss TC, et al. Hypertension after pancreas-kidney transplantation: role of bladder versus enteric pancreatic drainage. Transplantation 2000 Aug 15; 70(3): 494–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1996 Nov; 9(11): 121S–38S.PubMedCrossRefGoogle Scholar
  5. 5.
    Akioka K, Takahara S, Ichikawa S, et al. Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J Surg 2005 Feb; 29(2): 249–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002 Jul; 17(7): 1166–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Cross NB, Webster AC, Masson P, et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009 Jul 15; 88(1): 7–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002 Aug; 24(4): 479–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Caforio AL, Tona F, Piaserico S, et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005 Jan; 18(1): 116–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002 Oct; 16(5): 378–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Julien J, Farge D, Guillemain R, et al. Arterial hypertension in heart transplant recipients [French]. Presse Med 1990 Jan 6–13; 19(1): 26–9.PubMedGoogle Scholar
  12. 12.
    Pagnin E, Giacon B, Zaghetto F, et al. Arterial hypertension and oxidative stress induced by cyclosporine: effect of carvedilol [Italian]. Ann Ital Med Int 2001 Apr–Jun; 16(2): 101–5.PubMedGoogle Scholar
  13. 13.
    Rossi SJ, Schroeder TJ, Hariharan S, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993 Aug; 9(2): 104–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2009 Nov 12; 31(2): 95–103.PubMedCrossRefGoogle Scholar
  15. 15.
    Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010 Mar 1; 49(3): 141–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4(5): 281–97.PubMedCrossRefGoogle Scholar
  17. 17.
    Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009 Aug 15; 88(3 Suppl.): S62–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Dorababu M, Nishimura A, Prabha T, et al. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 2009 Nov; 63(9): 697–702.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stages after renal transplantation. Clin Transplant 2005 Oct; 19(5): 638–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006 May; 12(5): 775–80.CrossRefGoogle Scholar
  21. 21.
    Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993 Mar; 43(3): 706–11.PubMedCrossRefGoogle Scholar
  22. 22.
    McCulloch TA, Harper SJ, Donnelly PK, et al. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 1994 Sep; 47(9): 839–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010 Jan 4; 105(1 Suppl.): 21A–9A.PubMedCrossRefGoogle Scholar
  24. 24.
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996 Apr 11; 334(15): 939–45.PubMedCrossRefGoogle Scholar
  25. 25.
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997 Jun 28; 349(9069): 1857–63.CrossRefGoogle Scholar
  26. 26.
    Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001 Apr; 12(4): 822–7.PubMedGoogle Scholar
  27. 27.
    Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009 Nov; 22(11): 1073–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Formica Jr RN, Friedman AL, Lorber MI, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006 May; 21(5): 1389–94.PubMedCrossRefGoogle Scholar
  29. 29.
    Pesavento TE, Jones PA, Julian BA, et al. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996 Jun; 7(6): 831–5.PubMedGoogle Scholar
  30. 30.
    Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant 2007 Mar–Apr; 21(2): 277–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Cantarovich M, Hiesse C, Lockiec F, et al. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987 Oct; 28(4): 190–3.PubMedGoogle Scholar
  32. 32.
    Rump LC, Oberhauser V, Schwertfeger E, et al. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens 2000 Aug; 18(8): 1115–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999 Oct 23; 354(9188): 1415–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348(6): 538–49.PubMedCrossRefGoogle Scholar
  35. 35.
    Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002 Mar; 24(3): 330–50; discussion 29.PubMedCrossRefGoogle Scholar
  36. 36.
    Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996 Sep; 60(3): 341–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 2009 May; 21(5): 485–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006 Dec; 80(6): 646–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31(2): 95–103.PubMedCrossRefGoogle Scholar
  40. 40.
    Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002 Dec 27; 181–182; 299–303.PubMedCrossRefGoogle Scholar
  41. 41.
    Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Ann Rev Pharmacol Toxicol 2003; 43: 285–307.CrossRefGoogle Scholar
  42. 42.
    Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 Apr; 11(3): 217–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007 Jan; 63(1): 53–8.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Jingjing Cai
    • 1
  • Zhijun Huang
    • 1
  • Guoping Yang
    • 1
  • Ke Cheng
    • 2
  • Qifa Ye
    • 2
  • Yingzi Ming
    • 2
  • Xiaocong Zuo
    • 1
  • Peipei Zhou
    • 3
  • Hong Yuan
    • 1
  1. 1.Center of Clinical Pharmacology of the Third Xiangya HospitalCentral South UniversityChangsha, HunanPeople’s Republic of China
  2. 2.Center of Organ Transplantation of the Third Xiangya HospitalCentral South UniversityChangshaChina
  3. 3.Department of CardiologyA.O. Fox HospitalOneontaUSA

Personalised recommendations